{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:17:48Z","timestamp":1770707868332,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Vasopressin has achieved common usage for the treatment of catecholamine-requiring and catecholamine-resistant shock. Diabetes insipidus is a syndrome characterized by excretion of abnormally large volumes of dilute urine. To date, very few reports of diabetes insipidus after discontinuation of vasopressin infusion have been published; the majority of previous reports describe neurosurgical patients. The purpose of the present study was to investigate the occurrence rate of diabetes insipidus after discontinuation of vasopressin infusion among patients treated with vasopressin infusion for shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Retrospective analysis of electronic health records of patients receiving continuous vasopressin infusion for the treatment of shock within a 5-year period (2012\u20132016).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Medical, surgical, and cardiothoracic ICUs within one academic medical center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>One-thousand eight-hundred ninety-six patients received vasopressin infusion for the treatment of shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>The occurrence rate of diabetes insipidus after discontinuation of vasopressin infusion was 1.53% among all patients. Sixteen of 29 patients with diabetes insipidus after discontinuation of vasopressin infusion had undergone cardiothoracic intervention, such as coronary artery bypass graft and valve replacement surgery, extracorporeal membrane oxygenation, and placement of ventricular assist devices. No neurosurgical patients were identified in our cohort. In a control group of patients receiving norepinephrine but not vasopressin infusion for treatment of shock, criteria for diabetes insipidus were observed in two of 1,320 subjects (0.15%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Despite a paucity of published reports, diabetes insipidus after discontinuation of vasopressin infusion appears not to be a rare phenomenon, and is likely to be encountered by intensivists who regularly employ vasopressin for the treatment of vasoplegic shock. Previous reports consisted predominantly of neurosurgical patients. Our findings demonstrate the occurrence of diabetes insipidus after discontinuation of vasopressin infusion among patients with septic shock as well as vasoplegic shock after cardiothoracic intervention. The mechanism of diabetes insipidus after discontinuation of vasopressin infusion remains to be elucidated but may involve transient downregulation of V2 receptors induced by exposure to supraphysiological doses of vasopressin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004045","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T14:47:05Z","timestamp":1569336425000},"page":"e1008-e1013","source":"Crossref","is-referenced-by-count":13,"title":["Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock"],"prefix":"10.1097","volume":"47","author":[{"given":"Hannah","family":"Ferenchick","sequence":"first","affiliation":[{"name":"Division of Critical Care Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nail","family":"Cemalovic","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Montefiore Medical Center, Bronx, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter V.","family":"Dicpinigaitis","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230728","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13054-018-2102-1","article-title":"Definitions and pathophysiology of vasoplegic shock.","volume":"22","author":"Lambden","year":"2018","journal-title":"Crit Care"},{"key":"R2-20230728","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","article-title":"Vasopressin deficiency contributes to the vasodilation of septic shock.","volume":"95","author":"Landry","year":"1997","journal-title":"Circulation"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1053\/j.jvca.2017.10.032","article-title":"Vasoplegia after cardiovascular procedures-pathophysiology and targeted therapy.","volume":"32","author":"Shaefi","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R4-20230728","first-page":"885066617725255","article-title":"Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock.","author":"Hammond","year":"2017 Jan 1","journal-title":"J Intensive Care Med"},{"key":"R5-20230728","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/phar.2105","article-title":"Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock.","volume":"38","author":"Hammond","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","article-title":"Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study.","volume":"107","author":"D\u00fcnser","year":"2003","journal-title":"Circulation"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1749-8090-5-17","article-title":"Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-a double-blind randomized study.","volume":"5","author":"Papadopoulos","year":"2010","journal-title":"J Cardiothorac Surg"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/ALN.0000000000001434","article-title":"Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial.","volume":"126","author":"Hajjar","year":"2017","journal-title":"Anesthesiology"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1053\/j.jvca.2018.04.006","article-title":"Vasopressin in cardiac surgery: A meta-analysis of randomized controlled trials.","volume":"32","author":"D\u00fcnser","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beem.2016.02.007","article-title":"Diabetes insipidus: Differential diagnosis and management.","volume":"30","author":"Robertson","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R11-20230728","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cen.13866","article-title":"Diagnosis and management of central diabetes insipidus in adults.","volume":"90","author":"Garrahy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.24.5.541.33348","article-title":"Transient diabetes insipidus after discontinuation of therapeutic vasopressin.","volume":"24","author":"Kristeller","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"4_MeetingAbstracts","key":"R13-20230728","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.128.4_MeetingAbstracts.454S","article-title":"Transient acquired diabetes insipidus after vasopressin therapy for hypotension: A case report (abstract).","volume":"128","author":"Ramers","year":"2005","journal-title":"Chest"},{"key":"R14-20230728","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jtcvs.2008.06.032","article-title":"Vasopressin withdrawal associated with massive polyuria.","volume":"138","author":"Peskey","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R15-20230728","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1053\/j.jvca.2014.01.014","article-title":"Polyuria after cessation of vasopressin in a child after cardiac surgery.","volume":"28","author":"Bhaskar","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R16-20230728","first-page":"1042","article-title":"Iatrogenic central diabetes insipidus induced by vasopressin withdrawal.","volume":"1","author":"Shiber","year":"2015","journal-title":"Open J Clin Med Case Rep"},{"issue":"Suppl 12","key":"R17-20230728","first-page":"1678","article-title":"Transient diabetes insipidus upon discontinuation of a vasopressin infusion (abstract).","volume":"44","author":"Sundar","year":"2016","journal-title":"Crit Care Med"},{"key":"R18-20230728","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.wneu.2016.09.122","article-title":"Transient diabetes insipidus after discontinuation of vasopressin in neurological intensive care unit patients: Case series and literature review.","volume":"97","author":"Bohl","year":"2017","journal-title":"World Neurosurg"},{"key":"R19-20230728","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/jcpt.12627","article-title":"Diabetes insipidus after discontinuation of vasopressin infusion for septic shock.","volume":"43","author":"Rana","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"R20-20230728","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MAJ.0000000000000341","article-title":"Cardiac vasoplegia syndrome: Pathophysiology, risk factors and treatment.","volume":"349","author":"Omar","year":"2015","journal-title":"Am J Med Sci"},{"key":"R21-20230728","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00134-008-1279-1","article-title":"The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: A prospective, controlled study.","volume":"35","author":"Jochberger","year":"2009","journal-title":"Intensive Care Med"},{"key":"R22-20230728","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: Physiology, assessment and osmosensation.","volume":"282","author":"Bankir","year":"2017","journal-title":"J Intern Med"},{"key":"R23-20230728","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1152\/ajplegacy.1959.196.2.451","article-title":"Changes in urine concentration during prolonged administration of vasopressin and water.","volume":"196","author":"Levinsky","year":"1959","journal-title":"Am J Physiol"},{"key":"R24-20230728","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","article-title":"Vasopressin receptors.","volume":"11","author":"Birnbaumer","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"R25-20230728","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/endo.141.1.7256","article-title":"Vasopressin V2 receptor binding is down-regulated during renal escape from vasopressin-induced antidiuresis.","volume":"141","author":"Tian","year":"2000","journal-title":"Endocrinology"},{"key":"R26-20230728","doi-asserted-by":"crossref","first-page":"R354","DOI":"10.1152\/ajpregu.00065.2002","article-title":"Synergistic effects of nitric oxide and prostaglandins on renal escape from vasopressin-induced antidiuresis.","volume":"284","author":"Murase","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R27-20230728","doi-asserted-by":"crossref","first-page":"C1390","DOI":"10.1152\/ajpcell.00353.2004","article-title":"Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: Involvement of a lysosomal degradation pathway.","volume":"288","author":"Bouley","year":"2005","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T11:09:59Z","timestamp":1690542599000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004045","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}